MarketCapExport financials
DarioHealth Corp. (DRIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
DarioHealth Corp. Balance Sheet 2025-2011 | DRIO
Brief overview of DarioHealth Corp.'s balance sheet strength
The review uses the five latest available annual reports between 2015 and 2020.
Total assets increased by +597.4%, from $5.1 million to $35.4 million. A CAGR near 47.5% points to substantial expansion.
Growth in the asset base was not matched by liabilities: +597.4% versus +68.7%. The balance sheet moved in a more conservative direction.
The equity ratio reached 79.5% from -31.1%. A high capital share reduces dependence on liabilities.
The balance sheet holds more cash than interest-bearing debt; net debt is -$28.1 million, indicating minimal leverage.
Cash represents 80.7% of assets versus 52.6% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$143.2 million. It should be assessed alongside historical profits and capital distributions.
Overall assessment
The indicators point to a strong balance sheet position for DarioHealth Corp.: funding is balanced and liability risks appear controlled.
Annual Balance Sheet DarioHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
9.37 M | -3.79 M | -12.1 M | -31 M | -35.5 M | -28.1 M | -19.6 M | -11 M | -3.72 M | -1.09 M | -314 K | 1.3 M | -2.26 M | -1.23 M | - |
Long Term Debt |
30.7 M | 23.5 M | 24.6 M | 18.1 M | 21 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
430 K | 504 K | 111 K | 293 K | 266 K | 310 K | 317 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
32.8 M | 30.2 M | 25.8 M | 19.8 M | 846 K | 222 K | 455 K | - | 1 K | 7.49 M | 2.61 M | 4 M | 2.7 M | 2.82 M | - |
Total Current Liabilities |
9.32 M | 16.6 M | 12.5 M | 19.4 M | 14.4 M | 7.03 M | 5.22 M | 5.16 M | 3.02 M | 2.92 M | 1.69 M | 1.62 M | 1.51 M | - | - |
Total Liabilities |
- | - | - | - | - | 7.26 M | 5.68 M | 5.16 M | 3.02 M | 10.4 M | 4.3 M | 5.62 M | 4.2 M | 3.38 M | - |
Deferred Revenue |
714 K | 1.58 M | 997 K | 1.32 M | 1.2 M | 1.22 M | 1.22 M | 736 K | - | - | 31 K | 24 K | - | - | - |
Retained Earnings |
-452 M | -390 M | -349 M | -286 M | -222 M | -143 M | -110 M | -89.3 M | -71 M | -55 M | -43.4 M | -36.1 M | -20 M | -6.07 M | - |
Total Assets |
110 M | 119 M | 96.4 M | 119 M | 101 M | 35.4 M | 24.6 M | 14.1 M | 6.96 M | 3.87 M | 5.08 M | 3.08 M | 4.12 M | 2.32 M | - |
Cash and Cash Equivalents |
21.8 M | 27.8 M | 36.8 M | 49.4 M | 35.8 M | 28.6 M | 20.4 M | 11 M | 3.72 M | 1.09 M | 2.67 M | 1.45 M | 2.26 M | 1.23 M | - |
Book Value |
110 M | 119 M | 96.4 M | 119 M | 101 M | 28.2 M | 18.9 M | 8.92 M | 3.94 M | -6.54 M | 777 K | -2.54 M | -86.4 K | -1.07 M | - |
Total Shareholders Equity |
67.9 M | 72 M | 58.1 M | 80 M | 85.5 M | 28.2 M | 18.9 M | 8.92 M | 3.94 M | -6.54 M | -1.58 M | -5.3 M | -86 K | -1.07 M | 193 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet DarioHealth Corp.
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
571 K | 30.9 M | 765 K | 30.6 M | 30.5 M | 18.9 M | 23.5 M | 20.2 M | 23.4 M | 24.5 M | 24.6 M | 29 M | 29.1 M | 16.7 M | 18.1 M | 24 M | 23.1 M | 48 K | 21 K | 66 K | 125 K | 178 K | 222 K | 222 K | 222 K | 222 K | 455 K | 455 K | 455 K | 455 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
32.8 M | 31.5 M | 30.2 M | 33.5 M | 34.6 M | 22.7 M | 30.2 M | 32.6 M | 36.7 M | 41.1 M | 25.8 M | 30.4 M | 30.7 M | 18.4 M | 19.8 M | 25.9 M | 24.7 M | 48 K | 21 K | - | - | - | 222 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
714 K | 501 K | 1.58 M | 860 K | 727 K | 1.3 M | 1.58 M | 1.12 M | 1.52 M | 1.79 M | 997 K | 684 K | 789 K | 925 K | 1.32 M | 990 K | 999 K | 1.09 M | 1.2 M | 1.21 M | 1.31 M | 1.39 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 1.4 M | 1.3 M | 736 K | 385 K | 50 K | 736 K | - | - | - | - | - | - | - | 8 K | 31 K | 31 K | 31 K | 31 K | 24 K | 24 K | 24 K | 24 K | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-452 M | -460 M | -390 M | -442 M | -423 M | -404 M | -390 M | -378 M | -363 M | -359 M | -349 M | -334 M | -317 M | -299 M | -286 M | -273 M | -257 M | -238 M | -222 M | -200 M | -177 M | -159 M | -143 M | -143 M | -143 M | -143 M | -110 M | -110 M | -110 M | -110 M | -89.3 M | -89.3 M | -89.3 M | -89.3 M | -71 M | -71 M | -71 M | -71 M | -55 M | -55 M | -55 M | -55 M | -43.4 M | -43.4 M | -43.4 M | -43.4 M | -36.1 M | -36.1 M | -36.1 M | -36.1 M | -20 M | -20 M | -20 M | - | - | - | - | - | - | - | - | - |
Total Assets |
110 M | 103 M | 119 M | 118 M | 108 M | 116 M | 119 M | 110 M | 122 M | 137 M | 96.4 M | 107 M | 117 M | 108 M | 119 M | 126 M | 137 M | 127 M | 101 M | 117 M | 131 M | 124 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 6.96 M | 6.96 M | 6.96 M | 6.96 M | 3.87 M | 3.87 M | 3.87 M | 3.87 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | - | - | - | - |
Cash and Cash Equivalents |
27.8 M | 15 M | 36.8 M | 31.9 M | 22 M | 27.9 M | 27.8 M | 15.5 M | 22.9 M | 34.4 M | 36.8 M | 43.9 M | 52.6 M | 38.8 M | 49.4 M | 57.1 M | 67.9 M | 55.6 M | 35.8 M | 51.3 M | 63.9 M | 81.2 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 11 M | 11 M | 11 M | 11 M | 3.72 M | 3.72 M | 3.72 M | 3.72 M | 1.09 M | 1.09 M | 1.09 M | 1.09 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 1.45 M | 1.45 M | 1.45 M | 1.45 M | 2.26 M | 2.26 M | 2.26 M | 2.26 M | 1.23 M | 1.23 M | 1.23 M | 1.23 M | 909 K | - | - | - |
Book Value |
110 M | 103 M | 119 M | 118 M | 108 M | 116 M | 119 M | 110 M | 122 M | 137 M | 96.4 M | 107 M | 117 M | 108 M | 119 M | 126 M | 137 M | 127 M | 101 M | 117 M | 131 M | 124 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 6.96 M | 6.96 M | 6.96 M | 6.96 M | 3.87 M | 3.87 M | 3.87 M | 3.87 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | - | - | - | - |
Total Shareholders Equity |
72 M | 62.4 M | 58.1 M | 74.9 M | 64 M | 73.7 M | 72 M | 58.5 M | 68.1 M | 78 M | 58.1 M | 68 M | 78.4 M | 72 M | 80 M | 88.9 M | 99.7 M | 114 M | 85.5 M | 104 M | 118 M | 112 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 8.92 M | 8.92 M | 8.92 M | 8.92 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | -6.54 M | -6.54 M | -6.54 M | -6.54 M | -1.58 M | -1.58 M | -1.58 M | -1.58 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -86 K | -86 K | -86 K | -86 K | -1.07 M | -1.07 M | -1.07 M | -1.07 M | 193 K | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of DarioHealth Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
$ 1.85 | 3.0 % | $ 5.39 M | USA |
 |
Myriad Genetics
MYGN
|
$ 3.98 | 4.82 % | $ 369 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 1.73 | 0.73 % | $ 519 M | USA |
 |
Neuronetics
STIM
|
$ 1.89 | 3.45 % | $ 125 M | USA |
 |
Agilent Technologies
A
|
$ 172.97 | 0.07 % | $ 49.1 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 300.15 | 0.79 % | $ 14.9 B | USA |
 |
Biodesix
BDSX
|
$ 23.66 | 3.0 % | $ 179 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 12.9 | 6.78 % | $ 136 M |  China |
 |
Bioventus
BVS
|
$ 13.3 | 0.94 % | $ 886 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.65 | 11.61 % | $ 865 K | USA |
 |
Fulgent Genetics
FLGT
|
$ 19.81 | 1.57 % | $ 610 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Illumina
ILMN
|
$ 262.54 | 0.3 % | $ 40.7 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Laboratory Corporation of America Holdings
LH
|
$ 317.95 | 0.09 % | $ 26.5 B | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.7 | 0.03 % | $ 6.73 B | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.67 | 4.71 % | $ 86.7 K | USA |
 |
Medpace Holdings
MEDP
|
$ 618.47 | 1.94 % | $ 17.8 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 56.58 | 0.67 % | $ 2.65 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 622.29 | 0.12 % | $ 33.4 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 16.65 | 2.19 % | $ 2.13 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.81 | 0.73 % | $ 2.57 B | USA |
 |
CareDx, Inc
CDNA
|
$ 64.0 | 3.07 % | $ 3.41 B | USA |
 |
National Research Corporation
NRC
|
$ 20.15 | 3.33 % | $ 451 M | USA |
 |
Danaher Corporation
DHR
|
$ 229.04 | 3.04 % | $ 163 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 25.74 | 0.98 % | $ 24.4 B |  Niderland |
 |
Brainsway Ltd.
BWAY
|
$ 11.44 | 2.69 % | $ 389 M | Israel |
 |
Precipio
PRPO
|
$ 21.38 | 1.3 % | $ 34.3 M | USA |
 |
RadNet
RDNT
|
$ 68.8 | 1.81 % | $ 5.17 B | USA |
 |
Castle Biosciences
CSTL
|
$ 31.96 | 2.08 % | $ 926 M | USA |
 |
Guardant Health
GH
|
$ 158.6 | 1.77 % | $ 19.9 B | USA |
 |
Senseonics Holdings
SENS
|
$ 7.77 | 1.6 % | $ 324 M | USA |
 |
DexCom
DXCM
|
$ 86.04 | 0.07 % | $ 33.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 266.9 | 0.11 % | $ 45.9 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |